The latest Phase II data for Halozyme Therapeutics Inc.'s stromal depleting agent PEGPH20 lend some support for the use of one of the first biomarkers to emerge in pancreatic cancer – hyaluronan – as well as company's Phase III strategy, though the supportive results were not perfect.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?